Results

Total Results: 1,475 records

Showing results for "years".

1. Rate of Emergency Department (ED) visits related to suicidal ideation or suicide attempt by age group and State, 2017 | Agency for Healthcare Research and Quality
   www.monahrq.ahrq.gov/data/visualizations/ed-visit-suicidal-ideation.html
   February 01, 2021 - presents statistics on ED visits related to suicidal ideation or suicide attempt among individuals age 5 years … visits per 100,000 population related to suicidal ideation or suicide attempt for individuals ages 5-24 years … , 25-64 years, and 65+ years.

2. Celebrating 25 Years of the CAHPS Program | Agency for Healthcare Research and Quality
   www.monahrq.ahrq.gov/cahps/about-cahps/25timeline.html
   April 01, 2024 - Assessment of Healthcare Providers and Systems (CAHPS®) About CAHPS Celebrating 25 Years … Patient Experience CAHPS Announcements Contact CAHPS Celebrating 25 Years … of the CAHPS Program For 25 years, AHRQ has developed evidence-based surveys to support healthcare … homes Care for specific health conditions Health plans and related programs Access CAHPS ® : 25 Years … reviewed April 2024 Page originally created October 2020 Internet Citation: Celebrating 25 Years

3. Materials VI-A (pdf file)
   www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-164-materials-vi-a.pdf
   March 09, 2017 - 7 years 252,360 182,914 72.5% 67,567 36.9% 64,464 35.2% 52,907 28.9% 1,300 0.7% 541 8 years 242,915 … 0.4% 380 12 years 218,152 157,969 72.4% 61,099 38.7% 42,208 26.7% 18,861 11.9% 360 0.2% 276 13 years … years 184,371 116,226 63.0% 19,356 16.7% 1,013 0.9% 255 0.2% 10 0.0% 89 18 years 173,561 53,720 31.0% … 212 5 years 60,879 70,281 34.6% 103 50,472 55,741 27.5% 21 1,343 2,090 1.0% 11 157 6 years 57,026 … 13 years 24,633 30,372 20.1% 40 8,566 10,590 7.0% 11 231 338 0.2% 1 23 14 years 10,760 15,848 11.1%

4. Follow Up With Patient Family After Developmental Screening (pdf file)
   www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/preventive/chipra-202-tech-specs.pdf
   October 11, 2018 - Parents' Evaluation of Developmental Status (PEDS), birth - 8 years Non-recommended tools are those … " using "Ages and Stages Questionnaire (ASQ), 2 months - 5 years User Defined QDM Value Set (1.1.1.1) … " using "Bayley Infant Neuro-developmental Screen (BINS), 3 months - 2 years User Defined QDM Value Set … " using "Child Development Inventory (CDI), 18 months - 6 years User Defined QDM Value Set (1.1.1.1)" … " using "Child Development Review-Parent Questionnaire (CDR-PQ), 18 months - 5 years User Defined QDM

5. CHIPRA 212 Appendix 2 (pdf file)
   www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-212-appendix-2.pdf
   January 17, 2024 - CORTICOSTEROIDS (ICS) ICS NDC Code Brand Name Generic Product Name Route Drug ID Device FDA-Age (Years … and older N N N Y ICS NDC Code Brand Name Generic Product Name Route Drug ID Device FDA-Age (Years … Budesonide budesonide 0.5 mg/2 mL inhalation suspension inhalation d04276 Nebulizer 12 mon – 8 years … Budesonide budesonide 0.5 mg/2 mL inhalation suspension inhalation d04276 Nebulizer 12 mon – 8 years … and older N N N Y ICS NDC Code Brand Name Generic Product Name Route Drug ID Device FDA-Age (Years

6. National Collaborative for Innovation in Quality Measurement (pdf file)
   www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-177-section-2-technical-specs.pdf
   May 23, 2014 -  1-5 years  6-11 years  12-17 years  18-20 years  Total The total is the sum of the age … Daily Dose Criteria 13-17 years Average Daily Dose Criteria 18-20 years Asenapine Maleate >20 … Average Daily Dose Criteria 10-12 years Average Daily Dose Criteria 13-17 years Average Daily … Report three age stratifications and a total rate:  1–5 years.  6–11 years.  12–17 years. … Average Daily Dose Criteria for 10 12 years Average Daily Dose Criteria for 13 17 years Aripiprazole

7. Supplemental Document 2 (pdf file)
   www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/measure_retirement/supplemental-materials/supplementaldoc2.pdf
   September 01, 2014 - 3 years: 28% (5) Enrollees age 1 year: 19, 61 Age 2 years: 23, 50 Age 3 years: 18, 35 … Chlamydia Screening (females ages 16– 20 years) Sexually active females ages 16–20 years (MAX … Adolescent Well-Care Visits: Persons Ages 12– 21 Years Enrollees ages 12–17 years (MAX b ): … –6 years: 86, 92 Ages 7–11 years: 86, 93 Ages 12–19 years: 86, 92 Enrollees ages 12–24 … months: Mixed Ages 25 months–6 years: Downward Ages 7–11 years: Mixed Ages 12–19 years

8. CHIPRA 230: Technical Specifications (pdf file)
   www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-230-tech-specs.pdf
   July 12, 2019 - CHIPRA 230: Technical Specifications 1 The percentage of children, ages 2 through 17 years … For children ≥16 years of age, BMI score is sufficient. … Weight Classification Using BMI percentile, children 2 through 17 years of age can be classified into … Ages 2 through 17 years of age. … BMI score qualifies if child is 16 or 17 years of age.

9. CHIPRA 201: Section 2, Technical Specifications (pdf file)
   www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-201-asthma-section-2-tech-specs.pdf
   March 12, 2019 - Technical Specifications This measure assesses the percentage of children, ages 1 through 17 years … record data and is calculated as a percentage as follows: Percentage of children ages 1 through 17 years … Ages Children no younger than 1 year on January 1 of the measurement year but younger than 18 years … with (acute) exacerbation 493.92 Denominator The number of children ages 1 through 17 years … indicating cystic fibrosis or bronchiectasis (Table 2) Specification • Children younger than 6 years

10. CHIPRA 157: Section 6.B, Scientific Soundness of the Measure (pdf file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-157-section-6b.pdf
    August 10, 2018 - Ref. 6-12 years old / 0.324d 0.322d 0.325d 0.310d 0.310d 0.309d 1-5 years old / 0.728 0.726 0.735 … Ref. 6-12 years old / 0.324d 0.322d 0.325d 0.310d 0.310d 0.309d 1-5 years old / 0.728 0.726 0.735 … Ref. 6-12 years old / 0.329d 0.327d 0.327d 0.310d 0.310d 0.309d 1-5 years old / 0.738 0.735 0.739 … Ref. 6-12 years old / 0.411d 0.411d 0.413d 0.357d 0.359d 0.359d 1-5 years old / 0.893 0.892 0.904 … Ref. 6-12 years old / 0.411d 0.411d 0.413d 0.357d 0.358d 0.359d 1-5 years old / 0.894 0.893 0.905

11. Survey on Patient Safety (facility version) (doc file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/sops/surveys/hospital/facilscanform.doc
    November 15, 2019 - Less than 1 year ( d. 11 to 15 years ( b. 1 to 5 years ( e. 16 to 20 years ( c. 6 to 10 years … ( f. 21 years or more 2. … Less than 1 year ( d. 11 to 15 years (b. 1 to 5 years ( e. 16 to 20 years ( c. 6 to 10 years ( … f. 21 years or more 3. … Less than 1 year ( d. 11 to 15 years ( b. 1 to 5 years ( e. 16 to 20 years ( c. 6 to 10 years

12. MEASURE SUMMARY (CHIPRA Core Set Candidate Measures) - Control #: AS-1 (pdf file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/overview/background/measures-AS-1.pdf
    December 16, 2010 - Numerator: For 12-24 months, 25 months-6 years: One or more visits with a primary care physician during … For 7-11 years, 12-19 years: One or more visits with a primary care physician during the measurement … Denominator: Members who are 12 months through 24 months, 25 months through 6 years, 7 years through … 11 years, and 12 years through 19 years of age as of December 31 of the measurement year.

13. National Collaborative for Innovation in Quality Measurement--Metabolic Monitoring for Children and Adolescents on Antipsychotics (pdf file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-section-2-tech-specs.pdf
    November 01, 2014 - Specification – State Level Measure Description The percentage of children and adolescents 1 to 20 years … Eligible Population Ages 1 to 20 years by December 31 of the measurement year. …  1-5 years  6-11 years  12-17 years  18-20 years  Total. … Ages 1 year of age to 17 years as of December 31 of the measurement year. … Report three age stratifications and a total rate:  1–5 years.  6–11 years.  12–17 years.

14. Section 6.B, Validation Studies (pdf file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-156-section-6b.pdf
    January 01, 2013 - Ref. 6-12 Years Old / 0.908 0.929 0.946 0.946 0.948 0.947 1-5 Years Old / 0.795 0.809 0.775 0.774 … Ref. 6-12 Years Old / 0.906 0.928 0.944 0.944 0.947 0.947 1-5 Years Old / 0.795 0.808 0.775 0.774 … Ref. 6-12 Years Old / 0.895 0.916 0.936 0.936 0.940 0.941 1-5 Years Old / 0.788 0.800 0.772 0.771 … Ref. 6-12 years old / 0.324d 0.322d 0.325d 0.310d 0.310d 0.309d 1-5 years old / 0.729 0.727 0.735 … Ref. 6-12 years old / 0.325d 0.323d 0.325d 0.311d 0.311d 0.310d 1-5 years old / 0.731 0.729 0.737

15. 1b.4_Input_File_Specifications_508 (xls file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/toolkits/input-file-specifications.xlsx
    January 01, 2014 - medical claims source table Blank Blank Blank Note: Data for comorbidity claims cover a total of two years … had any comorbidities that involved the dermatological body system numeric (1/0) Calculated using 2 years … had any comorbidities that involved the genitourinary body system numeric (1/0) Calculated using 2 years … had any comorbidities that involved the hematological body system numeric (1/0) Calculated using 2 years … had any comorbidities that involved the immunological body system numeric (1/0) Calculated using 2 years

16. Attachment 7.1 Measure Performance by Race/Ethnicity: White (pdf file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-145-materials-vii-a.pdf
    January 01, 2010 - code in the measurement year (2011) Follow- % of Denominator up Visit 2010-2011 4-5 years … 245,024 126,173 51% 10,620 8% 2,489 23.43% 1,780 16.76% 5,703 53.70% 7,249 68.25% 6-12 years 713,045 … 377,224 53% 66,825 18% 14,798 22.14% 8,776 13.13% 34,675 51.88% 44,888 67.16% 13-18 years 490,828 … 10,055 7% 2,306 22.93% 1,331 13.24% 3,159 31.41% 5,131 51.03% 4-18 years 902,756 498,472 55% 45,574 … 5% 664 16.96% 411 10.50% 1,707 43.61% 2,204 56.30% 13-18 years 93,703 32,379 35% 950 3% 147 15.47%

17. Use of Multiple Concurrent Antipsychotics in Children Section 2, Technical Specifications (pdf file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-126-section-2-technical-specs.pdf
    April 30, 2018 - Children Administrative Specification Measure Description The percentage of children 0 to 20 years … Eligible Population Product Line Medicaid Ages 0 to 20 years by December 31 of the measurement year …  0-5 years  6-11 years  12-17 years  18-20 years  Total The total is the sum of the

18. Strategies to Better Manage Lipids – Statin Pearls
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/evidencenow/heart-health/strategies-to-better-manage-lipids.pptx
    November 01, 2016 - Population Recommendation Grade Adults ages 40-75 years with no symptoms or history of CVD and a calculated … for the prevention of CVD events when all of the following criteria are met: They are ages 40 to 75 years … and calculation of 10-year CVD event risk requires universal lipid screening in adults ages 40 to 75 years … #› 4 USPSTF Recommendation November 2016 (2) Population Recommendation Grade Adults ages 40-75 years … I Children and adolescents younger than age 20 years The USPSTF concludes that the current evidence

19. ABCS Aspirin Treatment for Secondary and Primary Prevention ASCVD
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/evidencenow/heart-health/aspirin-asa-measure.pptx
    April 01, 2016 - some stroke) Cardiovascular Disease (2) Leading killer Huge declines in CVD death in the past 20 years … , and are willing to take low-dose aspirin daily for at least 10 years. … Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and … ar1e willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. … and harms of aspirin use to prevent CVD and colorectal cancer in adults younger than age 50 years.

20. CHIPRA 155: Section 6.B, Scientific Soundness of the Measure (pdf file)
    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-155-section-6-b-measure.pdf
    January 01, 2013 - Ref. 6-12 years old / 0.779d 0.783d 0.729d 0.765d 0.765d 0.764d 1-5 years old / 0.639d 0.643d 0.561d … Ref. 6-12 years old / 0.502d 0.502d 0.513d 0.485d 0.485d 0.486d 1-5 years old / 0.969 0.968 1.008 … Ref. 6-12 years old / 0.457d 0.457d 0.459d 0.423d 0.424d 0.425d 1-5 years old / 0.976 0.976 0.973 … Ref. 6-12 years old / 0.461d 0.461d 0.462d 0.389d 0.390d 0.390d 1-5 years old / 0.970 0.970 0.976 … Ref. 6-12 years old / 0.432d 0.432d 0.429d 0.452a 0.452d 0.459d 1-5 years old / 1.037 1.037 1.023